Biology of Juvenile Myoclonic Epilepsy
ConditionJuvenile Myoclonic Epilepsy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10-40
SponsorKing's College London
About this trial
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Eligibility criteria
Qualifiers
Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
Age of myoclonus onset 10-25 years
Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
EEG interictal generalized spikes and/or polyspike and waves with normal background
Disqualifiers
Myoclonus only associated with carbamazepine or lamotrigine therapy
EEG showing predominant focal interictal epileptiform discharges or abnormal background
Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
Global learning disability
Trial design
Treatments tested in this trial
- Blood draw
- Existing samples
Treatment groups
1,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
King's College London
Lead sponsor
King's College Hospital NHS Trust
Collaborator
Charles University, Czech Republic
Collaborator
Hopital Universitaire Robert-Debre
Collaborator
Vestre Viken Hospital Trust
Collaborator
The Hospital for Sick Children
Collaborator
Cardiff University
Collaborator
Odense University Hospital
Collaborator
Source ClinicalTrials.gov